Tag: Dr Reddy’s

Dr. Reddy’s Laboratories is an Indian multinational pharmaceutical company based in Hyderabad, Telangana, India. The company was founded by Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited, of Hyderabad, India. Dr. Reddy’s manufactures and markets a wide range of pharmaceuticals in India and overseas. The company has over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology products.

Dr. Reddy’s announces the launch of generic version of Ocaliva®

Dr. Reddy’s Laboratories Ltd., announced the launch of FXR™, a therapeutic equivalent generic version of Ocaliva® (obeticholic acid) in India, indicated for the treatment of Primary Biliary Cholangiti...

Dr. Reddy’s Announces the Launch of Amphetamine Sulfate Tablets USP in the U.S.

Dr. Reddy’s Laboratories Ltd. announced the launch of Amphetamine Sulfate Tablets USP, a therapeutic equivalent generic version of Evekeo® (amphetamine sulfate) Tablets approved by the U.S. Food and D...

Dr. Reddy’s Is Voluntarily Recalling Four Lots of Phytonadione Injectable Emulsion USP

Dr. Reddy’s Laboratories Ltd. announced that it is voluntarily recalling four lots (ACB902, ACB903, ACB904, ACB905) of Phytonadione Injectable Emulsion USP, 10 mg/mL, Single-Dose Ampules to the hospit...

Wockhardt Selling Plant in Baddi to a Competitor – Dr. Reddy’s

India’s Wockhardt, which has had its financial fortunes dampened for several years by FDA-related manufacturing issues, has decided to improve its cash flow by selling a plant and portfolio of product...

Dr. Reddy’s Has Received Another Form 483 for a Plant that Makes APIs

Dr. Reddy’s has spent nearly five years trying to get out from under a warning letter for an important API plant in India but has yet to shake off all of the FDA’s concerns. In fact, a new FDA filing ...

Dr Reddy’s to Launch Fosaprepitant for Injection in US

Dr Reddy's Laboratories Ltd announced launch of Fosaprepitant for Injection the therapeutic generic equivalent of USFDA approved EMEND (fosaprepitant) for injection in the US market. We are pleased t...

FDA Approved Multiple Applications for First Generics of Lyrica

On July 19, the U.S. Food and Drug Administration approved multiple applications for first generics of Lyrica (pregabalin) for the management of neuropathic pain associated with diabetic peripheral ne...

Dr. Reddy’s to Sell Rights for Three Products

Dr. Reddy’s Laboratories Limited announces that it has entered into a definitive asset purchase agreement with Upsher-Smith Laboratories, LLC (Upsher-Smith), pursuant to which Dr. Reddy’s would sell i...

Dr. Reddy’s Launched Generic of Adcirca

Dr. Reddy’s Laboratories Ltd., along with its subsidiaries together referred to as “Dr. Reddy’s” announced the launch of Tadalafil Tablets USP, a therapeutic equivalent generic version of Adcirca (tad...

FDA Approval for Migrane Drug

Dr. Reddy's Laboratories Ltd. and its subsidiary, Promius Pharma, LLC today announced the approval of TOSYMRA (previously known as DFN-02) by the U.S. Food and Drug Administration (FDA). TOSYMRA is in...

Dr. Reddy’s to sale its API manufacturing business unit in India

dr reddy s
Dr. Reddy’s Laboratories entered into a definitive agreement for the sale of its API manufacturing business unit to Therapiva Private, an emerging generics pharmaceutical company.

Dr Reddy’s sells its US manufacturing facility to UAE pharma company

dr reddy s
Dr Reddy’s Laboratories has sold the antibiotics manufacturing facility and related assets it had acquired in Bristol, Tennessee (USA), from GlaxoSmithKline (GSK) seven years ago.

Dr Reddy’s recalls Atorvastatin Calcium from US market

Dr Reddy's Laboratories, an Indian multinational pharmaceutical company, is recalling from the USA over 236 000 bottles of Atorvastatin Calcium tablets used for lowering cholesterol.

Dr Reddy’s facility received six observations from German regulatory authority

dr reddys
Dr Reddys Laboratories informed that German regulatory authority has issued six major observations against its formulations unit

Dr Reddy’s out-licensed rights for a drug to US pharmaceutical company

dr reddys
Dr Reddy's Labs announced that it has out-licensed the future development, manufacturing, and commercialization rights of DFD-06, a topical high potency steroid, to Encore Dermatology Inc.

General Electric provides Dr. Reddy’s with manufacturing platform

dr reddys
GE Healthcare announced that Dr. Reddy’s Laboratories Limited will install India’s first-ever FlexFactory, a single-use manufacturing platform to expand the biologics production capacity at its facility in Hyderabad, India.